• PDF / 169,744 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 51 Downloads / 175 Views

DOWNLOAD

REPORT

---

1 S

Lack of efficacy: 3 case reports In a retrospective study of 561 patients who had undergone haematopoietic stem cell transplants between 1994 and 2015, 3 men aged 36–54 years were described, who exhibited lack of effect of during prophylactic antiviral therapy with lamivudine to prevent reactivation of hepatitis-B virus (HBV) or during treatment with lamivudine or tenofovir for HBV reactivation [dosages and routes not stated]. All the three men, who were positive to hepatitis-B surface antigen, were subjected to receive prophylactic lamivudine treatment (duration of prophylaxis was scheduled to be for 6 months, in two of the 3 men), following autologous or allogenic hematopoietic stem cell transplantation, in the setting of underlying multiple myeloma, acute myelogenous leukaemia M2 or non-Hodgkin lymphoma. Two of the 3 men developed HBV reactivation despite the prophylaxis; these two men received tenofovir treatment for HBV reactivation, which proved to be effective in one man; while the another man died eventually due to the fulminant hepatitis despite tenoofovir therapy. The remaining man developed HBV reactivation following completion of lamivudine prophylaxis. Lamivudine was reinitiated to treat the reactivation. However, lamivudine was found to be ineffective. Thereafter, the man underwent a trial of tenofovir. However, despite the tenofovir therapy, his condition progressed and he eventually died of fulminant hepatitis. Murt A, et al. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Annals of 803515126 Hematology 99: 2671-2677, No. 11, Nov 2020. Available from: URL: http://doi.org/10.1007/s00277-020-04206-z

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 14 Nov 2020 No. 1830